B7-H3 was initially introduced as co-stimulatory molecule for T cells, but has been proved as co-inhibitory checkpoint ligand, which can regulate helper T cells, cytotoxic T cells as well as Natural killer cells in human immunity. Since ADC technology allows a drug to be accurately delivered to a target cancer cell and released under specific conditions, while minimizing collateral damage to healthy cells, ADC technology increases the efficacy of a therapeutic antibody and decreases the risk of an adverse reaction.ī7-H3 (CD276) is a novel member of the B7 family and shares approximately up to 30% sequence homology. BACKGROUNDĪntibody-drug conjugates (ADCs) combine the binding specificity of antibodies with the potency of chemotherapeutic agents. The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. This application is incorporated herein by reference in its entirety. This application claims the benefit of priority to U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |